STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients

STAT+: Trump’s Medicaid work rules surprise states, patients

Structured plan for STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients, as new federal directives go beyond the original legislation and risk disenrolling millions, including those with disabilities, in a policy experts deem harmful to patient outcomes and market stability.

Key Takeaways

• New federal rules on Medicaid work requirements exceed the “Big Beautiful Bill” by giving states broad discretion to define medical frailty, putting at least 6.3 million Americans at risk of losing coverage, per the Center for American Progress.
• Three states — Nebraska, Montana, and Iowa — have already announced accelerated implementation through state plan amendments, well before the federal January 2027 deadline, forcing state health departments to redirect resources toward hiring staff and upgrading technology.
• Evidence from Arkansas’s 2018 work requirement experiment showed only 3–4% of those subject to the requirement were not working and did not qualify for exemptions, while those who lost coverage experienced worse health and economic outcomes — raising red flags for managed care organizations and pharmacy benefit managers.

What happened?

On June 3, 2026, STAT News reported that the Trump administration’s latest Medicaid work requirement directives go significantly beyond what lawmakers outlined in the House Republican “Big Beautiful Bill.” That legislation had carved out exemptions for pregnant women, people with disabilities, those caring for dependent children, and the “medically frail.” But the new federal rules give states wide latitude to define medical frailty, a standard health policy experts say is so vague that it will push disabled and chronically ill patients off the rolls. Medicaid leaders and advocates say they were shocked by the harshness of the directives.

Under the new rules, applicable individuals must prove they complete 80 hours of qualifying work activity per month. The burden of documentation and verification will fall on states, many of which are already struggling with redetermination backlogs. Nebraska was the first state to announce enforcement through a state plan amendment, starting May 1, 2026. Montana will follow on July 1, 2026, and Iowa on December 1, 2026 — all well before the federal January 2027 deadline. The accelerated timeline has caught state health departments off guard, forcing them to redirect resources into hiring staff, paying overtime, and upgrading aging technology, as Politico reported.

What does it mean for drugmakers and insurers?

For the pharmaceutical and health insurance industries, the new work requirements pose a direct threat to patient access and revenue stability. When patients lose Medicaid coverage, they often cannot afford out-of-pocket costs for needed care. In Arkansas, the 2018 work requirement experiment resulted in worse health and economic outcomes for those who lost coverage, with no measurable increase in employment. KFF’s overview of that period found that only 3 to 4 percent of those subject to the requirement were not working and did not qualify for exemptions, suggesting that the vast majority of disenrollments would hit people who were already exempt but failed to navigate the paperwork.

The current rules place heavy administrative burdens on state Medicaid agencies, which must now verify 80 hours of qualifying work activity per month. For managed care organizations and pharmacy benefit managers, the churn in enrollment will disrupt medication adherence, complicate risk adjustment, and increase the likelihood of uncompensated care. The Center for American Progress has estimated that at least 6.3 million Americans could be at risk of losing health coverage, a figure that underscores the magnitude of the potential disruption for healthcare markets. Drugmakers that rely on Medicaid for a significant share of their patient base — particularly those with products in diabetes, behavioral health, and HIV — should watch carefully how state-level implementation affects prescription volumes and adherence rates.

Frequently Asked Questions

Related coverage

• FDA seeks to cut repeat work for gene therapy developers